Cantor Fitzgerald Comments on TNGX FY2026 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Tango Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings per share of ($1.58) for the year. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02). The firm had revenue of $5.39 million for the quarter, compared to analyst estimates of $6.73 million. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of Tango Therapeutics in a report on Monday, April 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $12.20.

Tango Therapeutics Trading Up 6.5%

NASDAQ TNGX opened at $5.05 on Wednesday. The firm has a market cap of $547.39 million, a price-to-earnings ratio of -4.28 and a beta of 1.24. The company has a 50 day moving average of $1.95 and a 200-day moving average of $2.41. Tango Therapeutics has a 1-year low of $1.03 and a 1-year high of $12.02.

Institutional Trading of Tango Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of TNGX. TCG Crossover Management LLC bought a new position in Tango Therapeutics in the fourth quarter valued at approximately $33,174,000. Boxer Capital Management LLC bought a new position in Tango Therapeutics in the fourth quarter valued at approximately $32,077,000. Gilead Sciences Inc. bought a new position in shares of Tango Therapeutics during the fourth quarter worth $15,000,000. Farallon Capital Management LLC bought a new position in shares of Tango Therapeutics during the fourth quarter worth $12,360,000. Finally, Balyasny Asset Management L.P. boosted its position in shares of Tango Therapeutics by 22.0% during the fourth quarter. Balyasny Asset Management L.P. now owns 3,279,196 shares of the company’s stock worth $10,133,000 after purchasing an additional 592,000 shares in the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.